Patents by Inventor Mariam Albahrani

Mariam Albahrani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer Treatment
    Publication number: 20240101628
    Abstract: The present invention provides phagemid vectors and associated phagemid particles for cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or management of cancer.
    Type: Application
    Filed: September 22, 2023
    Publication date: March 28, 2024
    Applicant: Imperial College Innovations Limited
    Inventors: Amin Hajitou, Keittisak Suwan, Mariam Albahrani, Sajee Waramit
  • Cancer treatment
    Patent number: 11820792
    Abstract: The present invention provides phagemid vectors and associated phagemid particles for cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or management of cancer.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: November 21, 2023
    Assignee: Imperial College Innovations Limited
    Inventors: Amin Hajitou, Keittisak Suwan, Mariam Albahrani, Sajee Waramit
  • Cancer Treatment
    Publication number: 20200239535
    Abstract: The present invention provides phagemid vectors and associated phagemid particles for cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or management of cancer.
    Type: Application
    Filed: April 24, 2018
    Publication date: July 30, 2020
    Applicant: Imperial Innovations Limited
    Inventors: Amin Hajitou, Keittisak Suwan, Mariam Albahrani, Sajee Waramit